474 related articles for article (PubMed ID: 24829189)
1. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Kumar Kakkar A; Dahiya N
Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
[TBL] [Abstract][Full Text] [Related]
2. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
3. Big pharma moves from 'blockbusters' to 'niche busters'.
Dolgin E
Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
[No Abstract] [Full Text] [Related]
4. Financing drug discovery for orphan diseases.
Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
[TBL] [Abstract][Full Text] [Related]
5. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
6. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
7. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
8. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
9. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
10. Orphan Drugs and Their Impact on Pharmaceutical Development.
Attwood MM; Rask-Andersen M; Schiöth HB
Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
[TBL] [Abstract][Full Text] [Related]
11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
12. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
13. Quantifying emerging drugs for very rare conditions.
Miles KA; Packer C; Stevens A
QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
[TBL] [Abstract][Full Text] [Related]
14. [Orphan drugs : New opportunities for the treatment of rare diseases].
Beck M
Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
[TBL] [Abstract][Full Text] [Related]
15. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
16. Global pharmacogenomics: where is the research taking us?
Olivier C; Williams-Jones B
Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
[TBL] [Abstract][Full Text] [Related]
17. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
18. Orphan drug: Development trends and strategies.
Sharma A; Jacob A; Tandon M; Kumar D
J Pharm Bioallied Sci; 2010 Oct; 2(4):290-9. PubMed ID: 21180460
[TBL] [Abstract][Full Text] [Related]
19. Rare lung disease and orphan drug development.
Spagnolo P; du Bois RM; Cottin V
Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
[TBL] [Abstract][Full Text] [Related]
20. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]